This ExpertREACT article was originally published on 18 December 2008. Clinical data and pipeline positions described reflect the state of knowledge at that date.
RTS,S/AS: Phase II results in the NEJM
Phase II clinical trial results for GSK Biologicals' malaria vaccine candidate RTS,S/AS - developed in collaboration with the PATH Malaria Vaccine Initiative (MVI) - were published in the New England Journal of Medicine, generating significant attention across the global health and vaccine communities. The results of two new Phase II trials in both infants (under 1 year) and children aged 5-17 months showed that RTS,S/AS lowered the risk of malaria clinical episodes by more than 50% after long follow-up with an encouraging safety profile. Importantly, the vaccine - administered as three doses - did not appear to interfere with the protective immune response to co-administered EPI vaccines (Diphtheria, Tetanus, Pertussis, Hib) commonly given in malaria-endemic countries.
The advancement of RTS,S/AS towards planned Phase III studies was described as groundbreaking given the enormous disease burden of malaria - one of the world's leading infectious disease killers, predominantly affecting children in sub-Saharan Africa. While RTS,S/AS was already considered the most advanced malaria clinical candidate globally, Phase III would need to demonstrate efficacy across a larger and more geographically diverse population with longer follow-up to support regulatory submission. GSK confirmed one formulation - RTS,S/AS01 - as the Phase III candidate, with trials on track to start in 2009.
Implications for novel adjuvant systems
VacZine Analytics argued that beyond the malaria-specific implications, the results might also influence GSK's global push to gain acceptance for its novel adjuvant systems. RTS,S/AS contained MPL (3-O-desacyl-4'-monophosphoryl lipid A) and QS-21 (Stimulon), both derived from natural sources and both part of GSK's proprietary Adjuvant System (AS01/AS04). Approximately 60% of GSK's R&D pipeline incorporated one of these MPL-based systems. The company had invested an initial $300m acquisition cost in Corixa in 2005 to secure MPL rights. With Cervarix (containing AS04) still pending US FDA approval, any positive regulatory signal for MPL-containing vaccines - even in the malaria context - was viewed as supportive for the broader adjuvant technology programme.